<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32707914</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>15</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3320</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules25153320</ELocationID><Abstract><AbstractText>The 1,3-benzothiazole (BTZ) ring may offer a valid option for scaffold-hopping from indole derivatives. Several BTZs have clinically relevant roles, mainly as CNS medicines and diagnostic agents, with riluzole being one of the most famous examples. Riluzole is currently the only approved drug to treat amyotrophic lateral sclerosis (ALS) but its efficacy is marginal. Several clinical studies have demonstrated only limited improvements in survival, without benefits to motor function in patients with ALS. Despite significant clinical trial efforts to understand the genetic, epigenetic, and molecular pathways linked to ALS pathophysiology, therapeutic translation has remained disappointingly slow, probably due to the complexity and the heterogeneity of this disease. Many other drugs to tackle ALS have been tested for 20 years without any success. Dexpramipexole is a BTZ structural analog of riluzole and was a great hope for the treatment of ALS. In this review, as an interesting case study in the development of a new medicine to treat ALS, we present the strategy of the development of dexpramipexole, which was one of the most promising drugs against ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mignani</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, Universit&#xe9; Paris Descartes, PRES Sorbonne Paris Cit&#xe9;, CNRS UMR 860, 45, rue des Saints Peres, 75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CQM-Centro de Qu&#xed;mica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majoral</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse CEDEX 4, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Toulouse, 118 route de Narbonne, 31077 Toulouse CEDEX 4, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desaphy</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0001-8816-9369</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Universit&#xe0; degli Studi di Bari Aldo Moro, Piazza Giulio Cesare, 70124 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lentini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7079-5994</Identifier><AffiliationInfo><Affiliation>Dipartimento di Farmacia-Scienze del Farmaco, Universit&#xe0; degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>3FPU23BG52</RegistryNumber><NameOfSubstance UI="D014050">Toluene</NameOfSubstance></Chemical><Chemical><RegistryNumber>4433-52-7</RegistryNumber><NameOfSubstance UI="C058836">benzothiazoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="D000077487">Pramipexole</NameOfSubstance></Chemical><Chemical><RegistryNumber>D213B92S1Y</RegistryNumber><NameOfSubstance UI="C121565">pifithrin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077487" MajorTopicYN="N">Pramipexole</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014050" MajorTopicYN="N">Toluene</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1,3-benzothiazole (BTZ)</Keyword><Keyword MajorTopicYN="N">DrugBank</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">chronic neurodegenerative disorders</Keyword><Keyword MajorTopicYN="N">dexpramipexole</Keyword><Keyword MajorTopicYN="N">indoles</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32707914</ArticleId><ArticleId IdType="pmc">PMC7435757</ArticleId><ArticleId IdType="doi">10.3390/molecules25153320</ArticleId><ArticleId IdType="pii">molecules25153320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garg V., Maurya R.K., Thanikachalam P.V., Bansal G., Monga V. An insight into the medicinal perspective of synthetic analogs of indole: A review. Eur. J. Med. Chem. 2019;180:562&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">31344615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari A., Singh R.K. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorg. Chem. 2019;89:103021. doi: 10.1016/j.bioorg.2019.103021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2019.103021</ArticleId><ArticleId IdType="pubmed">31176854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart D.S., Feunang Y.D., Guo A.C., Lo E.J., Marcu A., Grant J.R., Sajed T., Johnson D., Li C., Sayeeda Z., et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074&#x2013;D1082. doi: 10.1093/nar/gkx1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1037</ArticleId><ArticleId IdType="pmc">PMC5753335</ArticleId><ArticleId IdType="pubmed">29126136</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerveri A., Bandini M. Recent advances in the catalytic functionalization of &#x201c;electrophilic&#x201d; indoles. Chin. J. Chem. 2020;38:287&#x2013;294. doi: 10.1002/cjoc.201900446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjoc.201900446</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy D., Hubbard T.D., Murray I.A., Perdew G.H. Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation. Drug Metab. Dispos. 2015;43:1522&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576673</ArticleId><ArticleId IdType="pubmed">26041783</ArticleId></ArticleIdList></Reference><Reference><Citation>Baell J.B., Holloway G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010;53:2719&#x2013;2740. doi: 10.1021/jm901137j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm901137j</ArticleId><ArticleId IdType="pubmed">20131845</ArticleId></ArticleIdList></Reference><Reference><Citation>Dvo&#x159;&#xe1;k Z., Kopp F., Costello C.M., Kemp J.S., Li H., Vrzalov&#xe1; A., &#x160;t&#x11b;p&#xe1;nkov&#xe1; M., Barto&#x148;kov&#xe1; I., Jiskrov&#xe1; E., Poul&#xed;kov&#xe1; K. Targeting the pregnane X receptor using microbial metabolite mimicry. EMBO Mol. Med. 2020;12:e11621. doi: 10.15252/emmm.201911621.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911621</ArticleId><ArticleId IdType="pmc">PMC7136958</ArticleId><ArticleId IdType="pubmed">32153125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzara P.R., Moore T.W. Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds. RSC Med. Chem. 2020;11:18&#x2013;29. doi: 10.1039/C9MD00396G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9MD00396G</ArticleId></ArticleIdList></Reference><Reference><Citation>Roughley S.D., Jordan A.M. The medicinal chemist&#x2019;s toolbox: An analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 2011;54:3451&#x2013;3479. doi: 10.1021/jm200187y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm200187y</ArticleId><ArticleId IdType="pubmed">21504168</ArticleId></ArticleIdList></Reference><Reference><Citation>Filz O.A., Poroikov V.V. Fragment-based lead design. Russian Chem. Rev. 2012;81:158&#x2013;174. doi: 10.1070/RC2012v081n02ABEH004222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1070/RC2012v081n02ABEH004222</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra C.B., Kumari S., Tiwari M. Thiazole: A promising heterocycle for the development of potent CNS active agents. Eur. J. Med. Chem. 2015;92:1&#x2013;34. doi: 10.1016/j.ejmech.2014.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.12.031</ArticleId><ArticleId IdType="pubmed">25544146</ArticleId></ArticleIdList></Reference><Reference><Citation>Naga Raju G., Karumudi B.S., Rao N.R. enzothiazole&#x2014;Versatile heterocyclic nucleus in medicinal chemistry: A review. B. Int. J. Pharm. Chem. 2015;5:104&#x2013;111.</Citation></Reference><Reference><Citation>Gleeson M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008;51:817&#x2013;834. doi: 10.1021/jm701122q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm701122q</ArticleId><ArticleId IdType="pubmed">18232648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualdani R., Tadini-Buoninsegni F., Roselli M.D.I., Contino M., Colabufo N.A., Lentini G. Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine. Pharmacol. Res. Perspect. 2015;3:e00160. doi: 10.1002/prp2.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.160</ArticleId><ArticleId IdType="pmc">PMC4618635</ArticleId><ArticleId IdType="pubmed">26516576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz-Oren I., Yalcin I., Ki-Sener E., Ucarturk N. Synthesis and structure-activity relationships of new antimicrobial active multisubstituted benzazole derivatives. Eur. J. Med. Chem. 2004;39:291&#x2013;298. doi: 10.1016/j.ejmech.2003.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2003.11.014</ArticleId><ArticleId IdType="pubmed">15051178</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A.K., Martin A., Singh A.K. Synthesis, characterization and evaluation of anti-inflammatory and analgesic activity of benzothiazole derivatives. Indian J. Pharm. Biol. Res. 2014;2:84&#x2013;89. doi: 10.30750/ijpbr.2.3.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.30750/ijpbr.2.3.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillane C.B., Fletcher N.C., Rountree S.M., van Den B.H., Chanduloy S., Morgan J.L., Keene F.R. Benzothiazole bipyridine complexes of ruthenium(II) with cytotoxic activity. J. Biol. Inorg. Chem. 2007;12:797&#x2013;807. doi: 10.1007/s00775-007-0232-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00775-007-0232-z</ArticleId><ArticleId IdType="pubmed">17530304</ArticleId></ArticleIdList></Reference><Reference><Citation>Desaphy J.-F., Carbonara R., Costanza T., Conte Camerino D. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. Exp. Neurol. 2014;255:96&#x2013;102. doi: 10.1016/j.expneurol.2014.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.02.023</ArticleId><ArticleId IdType="pmc">PMC4004800</ArticleId><ArticleId IdType="pubmed">24613829</ArticleId></ArticleIdList></Reference><Reference><Citation>Amnerkar N.D., Bhusari K.P. Synthesis, Anticonvulsant Activity and 3D-QSAR Study of Some prop-2-eneamido and 1-acetyl-pyrazolin Derivatives of Aminobenzothiazole. Eur. J. Med. Chem. 2010;45:149&#x2013;159. doi: 10.1016/j.ejmech.2009.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2009.09.037</ArticleId><ArticleId IdType="pubmed">19853976</ArticleId></ArticleIdList></Reference><Reference><Citation>Plesnila N., Von B.L., Retiounskaia M., Engel D., Ardeshiri A., Zimmermann R., Hoffmann F., Landshamer S., Wagner E., Culmsee C. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell. Death Differ. 2007;14:1529&#x2013;1541. doi: 10.1038/sj.cdd.4402159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402159</ArticleId><ArticleId IdType="pubmed">17464322</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert A. Chemical aspects of selective toxicity. Nature. 1958;182:421&#x2013;423. doi: 10.1038/182421a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/182421a0</ArticleId><ArticleId IdType="pubmed">13577867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignani S., Huber S., Tom&#xe1;s H., Rodrigues J., Majoral J.-P. Compound high-quality criteria: A new vision to guide the development of drugs, current situation. Drug Discov. Today. 2016;21:573&#x2013;584. doi: 10.1016/j.drudis.2016.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2016.01.005</ArticleId><ArticleId IdType="pubmed">26802700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalluzzi M.M., Mangiatordi G.F., Nicolotti O., Lentini G. Ligand efficiency metrics in drug discovery: The pros and cons from a practical perspective. Exp. Opin. Drug Discv. 2017;12:1087&#x2013;1104. doi: 10.1080/17460441.2017.1365056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2017.1365056</ArticleId><ArticleId IdType="pubmed">28814111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997;23:3&#x2013;25. doi: 10.1016/S0169-409X(96)00423-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(96)00423-1</ArticleId><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002;45:2615&#x2013;2623. doi: 10.1021/jm020017n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm020017n</ArticleId><ArticleId IdType="pubmed">12036371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghose A.K., Viswanadhan V.N., Wendoloski J.J.A. Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999;1:55&#x2013;68. doi: 10.1021/cc9800071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cc9800071</ArticleId><ArticleId IdType="pubmed">10746014</ArticleId></ArticleIdList></Reference><Reference><Citation>Oprea T.I. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des. 2000;14:251&#x2013;264. doi: 10.1023/A:1008130001697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1008130001697</ArticleId><ArticleId IdType="pubmed">10756480</ArticleId></ArticleIdList></Reference><Reference><Citation>Congreve M., Carr R., Murray C., Jhoti H. A &#x201c;rule of three&#x201d; for fragment-based lead discovery? Drug Discov. Today. 2003;8:876&#x2013;877. doi: 10.1016/S1359-6446(03)02831-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(03)02831-9</ArticleId><ArticleId IdType="pubmed">14554012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovering F., Bikker J., Humblet C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009;52:6752&#x2013;6756. doi: 10.1021/jm901241e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm901241e</ArticleId><ArticleId IdType="pubmed">19827778</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D.A., Di L., Kerns E.H. The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery. Nat. Rev. Drug Discov. 2010;9:929&#x2013;939. doi: 10.1038/nrd3287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3287</ArticleId><ArticleId IdType="pubmed">21119731</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Wright M., Hop C.E.C.A. Rational Use of Plasma Protein and Tissue Binding Data in Drug Design. J. Med. Chem. 2014;57:8238&#x2013;8248. doi: 10.1021/jm5007935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5007935</ArticleId><ArticleId IdType="pubmed">25099658</ArticleId></ArticleIdList></Reference><Reference><Citation>Trainor G.L. The importance of plasma protein binding in drug discovery. Exp. Opin. Drug Discov. 2007;2:51&#x2013;64. doi: 10.1517/17460441.2.1.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2.1.51</ArticleId><ArticleId IdType="pubmed">23496037</ArticleId></ArticleIdList></Reference><Reference><Citation>Meanwell N.A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 2011;24:1420&#x2013;1456. doi: 10.1021/tx200211v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/tx200211v</ArticleId><ArticleId IdType="pubmed">21790149</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lange E.C.M., van den Brink W., Yamamoto Y., de Witte W.E.A., Wong Y.C. Novel CNS drug discovery and development approach: Model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Exp. Opin. Drug Discov. 2017;12:1207&#x2013;1218. doi: 10.1080/17460441.2017.1380623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2017.1380623</ArticleId><ArticleId IdType="pubmed">28933618</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X.X., Wang Y., Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 2009;30:379&#x2013;387. doi: 10.1038/aps.2009.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2009.24</ArticleId><ArticleId IdType="pmc">PMC4002277</ArticleId><ArticleId IdType="pubmed">19343058</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Espejo E. Pathogenesis of Parkinson&#x2019;s disease: Prospects of neuroprotective and restorative therapies. Mol. Neurobiol. 2004;29:15&#x2013;30. doi: 10.1385/MN:29:1:15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:29:1:15</ArticleId><ArticleId IdType="pubmed">15034220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli R.M., Wenning G.K., Kapfhammer H.P. Huntington&#x2019;s disease: Present treatments and future therapeutic modalities. Int. Clin. Psychopharmacol. 2004;19:51&#x2013;62. doi: 10.1097/00004850-200403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004850-200403000-00001</ArticleId><ArticleId IdType="pubmed">15076012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ates O., Cayli S.R., Gurses I., Karabulut A.B., Yucel N., Kocak A., Cakir C.O., Yologlu S. Do sodium channel blockers have neuroprotective effect after onset of ischemic insult? Neurol. Res. 2007;29:317&#x2013;323. doi: 10.1179/016164107X159225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164107X159225</ArticleId><ArticleId IdType="pubmed">17509233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V.A. Controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryson H.M., Fulton B., Benfield P. Riluzole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drug Eval. 1996;52:549&#x2013;563. doi: 10.2165/00003495-199652040-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-199652040-00010</ArticleId><ArticleId IdType="pubmed">8891467</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2002;2:CD001447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M., Smith A. Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener. Neurol. Neuromuscul. Dis. 2017;7:61&#x2013;70. doi: 10.2147/DNND.S135748.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S135748</ArticleId><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T., Kiernan M.C. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17:385&#x2013;386. doi: 10.1016/S1474-4422(18)30091-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30091-7</ArticleId><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzmann H. Withdrawal of Radicava, (Edaravone), 30 mg Solution for Infusion-EMEA/H/C/004938/0000.  [(accessed on 24 May 2019)]; Available online:  https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-radicava_en.pdf.</Citation></Reference><Reference><Citation>Camerino G.M., Fonzino A., Conte E., De Bellis M., Mele A., Liantonio A., Tricarico D., Tarantino N., Dobrowolny G., Musar&#xf2; A., et al. Elucidating the contribution of skeletal muscle ion channels to amyotrophic lateral sclerosis in search of new therapeutic options. Sci. Rep. 2019;9:3185. doi: 10.1038/s41598-019-39676-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39676-3</ArticleId><ArticleId IdType="pmc">PMC6395744</ArticleId><ArticleId IdType="pubmed">30816241</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacilla G., Sari Y. Potential therapeutic drugs and methods for the treatment of amyotropic lateral sclerosis. Curr. Med. Chem. 2014;21:3583&#x2013;3593. doi: 10.2174/0929867321666140601162710.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140601162710</ArticleId><ArticleId IdType="pmc">PMC4182116</ArticleId><ArticleId IdType="pubmed">24934355</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233&#x2013;S241. doi: 10.1212/WNL.47.6_Suppl_4.233S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.233S</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D., Thompson M.A., Nadler J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 1993;250:473&#x2013;476. doi: 10.1016/0014-2999(93)90037-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(93)90037-I</ArticleId><ArticleId IdType="pubmed">8112408</ArticleId></ArticleIdList></Reference><Reference><Citation>Frizzo M.E., Dall&#x2019;Onder L.P., Dalcin K.B., Souza D.O. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell. Mol. Neurobiol. 2004;24:123&#x2013;128. doi: 10.1023/B:CEMN.0000012717.37839.07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:CEMN.0000012717.37839.07</ArticleId><ArticleId IdType="pubmed">15049516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt J., Schmidt T., Golla M., Lehmann L., Weber J.J., H&#xfc;bener-Schmid J., Riess O. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. J. Neurochem. 2016;138:150&#x2013;162. doi: 10.1111/jnc.13606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13606</ArticleId><ArticleId IdType="pubmed">26990650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala G., Arosio A., Conti E., Beretta S., Lunetta C., Riva N., Ferrarese C., Tremolizzo L. Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes. Clin. Psychopharmacol. Neurosci. 2019;17:438&#x2013;442. doi: 10.9758/cpn.2019.17.3.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2019.17.3.438</ArticleId><ArticleId IdType="pmc">PMC6705104</ArticleId><ArticleId IdType="pubmed">31352711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanzadeh K., Habibi-asl B., Roshangar L., Nemati M., Ansarin M., Farajnia S. Intracerebroventricular administration of riluzole prevents morphine-induced apoptosis in the lumbar region of the rat spinal cord. Pharmacol. Rep. 2010;62:664&#x2013;673. doi: 10.1016/S1734-1140(10)70323-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(10)70323-6</ArticleId><ArticleId IdType="pubmed">20885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Selin &#xdc;st&#xfc;n Bezgin S., Uygur K.K., G&#xf6;kdo&#x11f;an C., Elmas C., G&#xf6;kta&#x15f; G. The effects of riluzole on cisplatin-induced ototoxicity. Int. Arch. Otorhinolaryngol. 2019;23:e267&#x2013;e275. doi: 10.1055/s-0038-1676654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1676654</ArticleId><ArticleId IdType="pmc">PMC6660296</ArticleId><ArticleId IdType="pubmed">31360245</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: Anupdate of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimonet P., Audiau F., Barreau M., Blanchard J.-C., Boireau A., Bour Y., Coleno M.-A., Doble A., Doerflinger G., Do Huu C., et al. Riluzole series. Synthesis and in vivo &#x201c;antiglutamate&#x201d; activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J. Med. Chem. 1999;42:2828&#x2013;2843. doi: 10.1021/jm980202u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980202u</ArticleId><ArticleId IdType="pubmed">10425092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney J.B., Rattray M., Pugh V., Powell L.A. Riluzole&#x2212;triazole hybrids as novel chemical probes for neuroprotection in amyotrophic lateral sclerosis. ACS Med. Chem. Lett. 2018;9:552&#x2013;556. doi: 10.1021/acsmedchemlett.8b00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.8b00103</ArticleId><ArticleId IdType="pmc">PMC6004570</ArticleId><ArticleId IdType="pubmed">29937981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B., Lu C.H., Greensmith L. The role of heat shock proteins in amyotrophic lateral sclerosis: The therapeutic potential of arimoclomol. Pharmacol. Ther. 2014;141:40&#x2013;54. doi: 10.1016/j.pharmthera.2013.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.08.003</ArticleId><ArticleId IdType="pubmed">23978556</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M., Yamashita T., Hirose N., Teramoto S., Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep. 2016;6:28649. doi: 10.1038/srep28649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., Cudkowicz M.E., Sarah Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D., Hayden D., Shui A., Brooks B., et al. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: Results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2014;13:1083&#x2013;1091. doi: 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E., Ogino M., Iwamoto K., Kitagawa Y., Iwasaki Y., Yoshii F., Ikeda J.E. Bromocriptine mesylate attenuates amyotrophic lateral sclerosis: A phase 2a, randomized, double-blind, placebo-controlled research in Japanese patients. PloS ONE. 2016;24:e0149509. doi: 10.1371/journal.pone.0149509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149509</ArticleId><ArticleId IdType="pmc">PMC4765990</ArticleId><ArticleId IdType="pubmed">26910108</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti G. Treatment of Amyotrophic Lateral Sclerosis with Nimesulide. 20060041022A1. U.S. Patent. 2006 Feb 23;</Citation></Reference><Reference><Citation>Goutman S.A., Savelieff M.G., Sakowski S.A., Feldman E.L. Stem cell treatments for amyotrophic lateral sclerosis: A critical overview of early phase trials. Expert Opin. Investig. Drugs. 2019;28:525&#x2013;543. doi: 10.1080/13543784.2019.1627324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2019.1627324</ArticleId><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS.  [(accessed on 22 July 2020)]; Available online:  https://www.sciencedaily.com/releases/2018/05/180521131659.htm.</Citation></Reference><Reference><Citation>Domino E.F., Unna K.R., Kerwin J. Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action. J. Pharmacol. Exp. Ther. 1952;105:486&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">14955779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunakkunru A., Verma S.M. Quantitative structure activity relationship of riluzole series as anticonvulsants. Asian J. Chem. 2007;19:2843&#x2013;2849.</Citation></Reference><Reference><Citation>Zhu X., Yu Q.S., Cutler R.G., Culmsee C.W., Holloway H.W., Lahiri D.K., Mattson M.P., Greig N.H. Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-Imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J. Med. Chem. 2002;45:5090&#x2013;5097. doi: 10.1021/jm020044d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm020044d</ArticleId><ArticleId IdType="pubmed">12408720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gribkoff V.K., Bozik M.E. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrocholride monohydrate] for the treatment of amyatropic lateral sclerosis. CNS Neurosci. Ther. 2008;14:215&#x2013;226. doi: 10.1111/j.1755-5949.2008.00048.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2008.00048.x</ArticleId><ArticleId IdType="pmc">PMC6494033</ArticleId><ArticleId IdType="pubmed">18801114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Toninelli G., Maccarinelli G., Uberti D., Buerger E., Memo M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol. 2010;10:2. doi: 10.1186/1471-2210-10-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2210-10-2</ArticleId><ArticleId IdType="pmc">PMC2829550</ArticleId><ArticleId IdType="pubmed">20137065</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini A., Barone P., Ceravolo R., Fabbrini G., Tinazzi M., Abbruzzese G. Role of pramipexole in the management of Parkinson&#x2019;s disease. CNS Drugs. 2010;24:829&#x2013;841. doi: 10.2165/11585090-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11585090-000000000-00000</ArticleId><ArticleId IdType="pubmed">20839895</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinato A., Altamura C., Desaphy J.F. Effects of Benzothiazolamines on voltage-gated sodium channels. Handb. Exp. Pharmacol. 2018;246:230&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">28939972</ArticleId></ArticleIdList></Reference><Reference><Citation>Urru M., Muzzi M., Coppi E., Ranieri G., Buonvicino D., Camaioni E., Coppini R., Pugliese A.M., Tanaka B., Estacion M., et al. Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models. Pain. 2020;161:831&#x2013;841. doi: 10.1097/j.pain.0000000000001774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000001774</ArticleId><ArticleId IdType="pubmed">31815915</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira F.G., LaDow E., Moreno A., Kidd J.D., Thompson K., Gill A., Finkbeiner S., Perrin S. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLOS ONE. 2014;19:e91608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272269</ArticleId><ArticleId IdType="pubmed">25526593</ArticleId></ArticleIdList></Reference><Reference><Citation>Javan N.B., Omid N.J., Hasb N.M., Shirmard L.R., Rafiee-Tehrani M., Dorkoosh F. Preparation, statistical optimization and in vitro evaluation of pramipexole prolonged delivery system based on (3-hydroxybutyrate-co-3-hydroxyvalerate nanoparticles. J. Drug Deliv. Sci. Technol. 2018;44:82&#x2013;90. doi: 10.1016/j.jddst.2017.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2017.11.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkwalder C., Hening W.A., Montagna P., Oertel W.H., Allen R.P., Walters A.S., Costa J., Stiasny-Kolster K., Sampaio C. Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. MoV. Disord. 2008;23:2267&#x2013;22302. doi: 10.1002/mds.22254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22254</ArticleId><ArticleId IdType="pubmed">18925578</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzzia M., Buonvicino D., Urru M., Ofani L., Chiarugi A. Repurposing of dexpramipexole to treatment of neonatal hypoxic/ischemic encephalopathy. Neurosci. Lett. 2018;687:234&#x2013;240. doi: 10.1016/j.neulet.2018.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.09.064</ArticleId><ArticleId IdType="pubmed">30287306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya R.S., Zhu H., Li W., Bowser R., Friedlander R.M., Wang X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2013;70:4729&#x2013;4745. doi: 10.1007/s00018-013-1415-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1415-0</ArticleId><ArticleId IdType="pmc">PMC4172456</ArticleId><ArticleId IdType="pubmed">23864030</ArticleId></ArticleIdList></Reference><Reference><Citation>Juarez J.M., Silva Guisasola G.O. Method for the Resolution of 2-amino-6-propilamino-4,5,6,7 Tetrahydrobenzothiazol and Intermediate Compounds. Application No. 2006120268A1. WO Patent. 2006 Nov 16;</Citation></Reference><Reference><Citation>Siesel D.A., Ramirez C., Meckler H. Process for Preparing Chirality Pure 2-amino-6-(alkyl)amino-4,5,6,7-tetrahydrobenzothiazoles by Liquid Chromatographic Resolution. Application No. 200612276A1. WO Patent. 2006 Feb 2;</Citation></Reference><Reference><Citation>Zivec M., Anzic B., Gobec S. A novel scalable synthesis of pramipexole. Org. Process. Res. Dev. 2010;14:1125&#x2013;1129. doi: 10.1021/op1000989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/op1000989</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider C.S., Mierau J. Dopamine autoreceptor agonists: Resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. J. Med. Chem. 1987;30:494&#x2013;498. doi: 10.1021/jm00386a009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00386a009</ArticleId><ArticleId IdType="pubmed">3820220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraboschi P., Ciceri S., Ciuffreda P., De Mieri M., Romano D., Grisenti P. Baker&#x2019;s yeast catalyzed preparation of a new enathiomerically pure synthon of (S)-pramipexole and its enatiomer (dexpramipexole) Tetrahedron Asymmetry. 2014;25:1239&#x2013;1245. doi: 10.1016/j.tetasy.2014.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tetasy.2014.07.011</ArticleId></ArticleIdList></Reference><Reference><Citation>News and Events-KNOPP Bioscience.  [(accessed on 6 September 2017)]; Available online:  https://knoppbio.com/index.php?section=news&amp;subsection=news&amp;id=56.</Citation></Reference><Reference><Citation>Wang H., Larriviere K.S., Keller K.E., Ware K.A., Burns T.M., Conaway M.A., Lacomis D., Pattee G., Philipps L.H., Solenski N.J.Z., et al. R(+)pramipexole as a mitochondrally focused neuroprotectant: Initial early phase studies in ALS. ALS. 2008;9:50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">18270879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M., Bozik M.E., Ingersoll E.W., Miller R., Mitsumoto H., Shefner J., Moore D.H., Schoenfeld D., Mather J.L., Archibald D., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat. Med. 2011;17:1652&#x2013;1666. doi: 10.1038/nm.2579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2579</ArticleId><ArticleId IdType="pubmed">22101764</ArticleId></ArticleIdList></Reference><Reference><Citation>Panch S.R., Bozik M.E., Brown T., Makiya M., Prussin C., Archibald D.G., Hebrank G.T., Sullivan M., Sun X., Wetzler L., et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018;132:501&#x2013;509. doi: 10.1182/blood-2018-02-835330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-02-835330</ArticleId><ArticleId IdType="pmc">PMC6073324</ArticleId><ArticleId IdType="pubmed">29739754</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutical Daily-Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma.  [(accessed on 22 July 2020)]; Available online:  http://www.pharmaceuticaldaily.com/knopp-biosciences-enters-collaboration-with-leading-uk-investigators-to-commence-phase-2-clinical-trial-of-dexpramipexole-in-severe-eosinophilic-asthma.</Citation></Reference><Reference><Citation>Majoral J.P., Zablocka M., Koprowski M., Hameau A., Shi X., Mignani S., Caminade A.M. Design, complexing and catalytic properties of phosphorus thiazoles and benzothiazoles: A concise overview. New J. Chem. 2019;43:16785&#x2013;16795. doi: 10.1039/C9NJ02966D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NJ02966D</ArticleId></ArticleIdList></Reference><Reference><Citation>Majoral J.P., Zablocka M., Caminade A.M., Balczewski P., Shi X., Mignani S. Interactions gold/phosphorus dendrimers.Versatile ways to hybrid organic-metallic macromolecules. Coord. Chem. Rev. 2018;358:80&#x2013;91. doi: 10.1016/j.ccr.2017.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2017.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorme T., De Bock K., Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Alnabulsi S., Al-Hurani E., Al-Shar&#x2019;i N.A., El-Elimat T. Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design. J. Mol. Graph. Model. 2019;93:107440. doi: 10.1016/j.jmgm.2019.107440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2019.107440</ArticleId><ArticleId IdType="pubmed">31494535</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>